Codominant interference, antieffectors, and multitarget drugs.
暂无分享,去创建一个
[1] R. Weinberg,et al. The retinoblastoma protein and cell cycle control , 1995, Cell.
[2] J. Inman,et al. A deeply recessed active site in angiotensin-converting enzyme is indicated from the binding characteristics of biotin-spacer-inhibitor reagents. , 1990, Biochemical and biophysical research communications.
[3] E. Vitetta,et al. Immunotoxins: an update. , 1996, Annual review of immunology.
[4] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins , 1997, Science.
[5] J. Bishop. Cancer: the rise of the genetic paradigm. , 1995, Genes & development.
[6] S. Rosenberg,et al. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. , 1996, Annual review of medicine.
[7] K. Kinzler,et al. Lessons from Hereditary Colorectal Cancer , 1996, Cell.
[8] D. Ringe,et al. Locating and characterizing binding sites on proteins , 1996, Nature Biotechnology.
[9] A. Varshavsky. The N-end rule. , 1995, Cold Spring Harbor symposia on quantitative biology.
[10] A. Fattaey,et al. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.
[11] S. Schreiber,et al. Three-part inventions: intracellular signaling and induced proximity. , 1996, Trends in biochemical sciences.
[12] Bert Vogelstein,et al. Cell-cycle arrest versus cell death in cancer therapy , 1997, Nature Medicine.
[13] K. Kinzler,et al. Converting cancer genes into killer genes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[14] Louis S. Goodman,et al. The Pharmacological Basis of Therapeutics. , 1941 .
[15] Takimoto Ch,et al. New Antifolates in Clinical Development , 1995 .
[16] M. Swindells,et al. Protein clefts in molecular recognition and function. , 1996, Protein science : a publication of the Protein Society.
[17] A. Knudson,et al. Antioncogenes and human cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.